Report cover image

Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 197 Pages
SKU # APRC20355521

Description

Summary

According to APO Research, The global DPP-4 Inhibitors for Type 2 Diabetes Treatment market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for DPP-4 Inhibitors for Type 2 Diabetes Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of DPP-4 Inhibitors for Type 2 Diabetes Treatment include Novartis, Merck, Eli Lilly and Company, AstraZeneca, Takeda Pharmaceutical, Sanwa Kagaku Kenkyusho, Mitsubishi Tanabe Pharma, LG Life Sciences and Dong-A Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for DPP-4 Inhibitors for Type 2 Diabetes Treatment, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of DPP-4 Inhibitors for Type 2 Diabetes Treatment, also provides the sales of main regions and countries. Of the upcoming market potential for DPP-4 Inhibitors for Type 2 Diabetes Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the DPP-4 Inhibitors for Type 2 Diabetes Treatment sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global DPP-4 Inhibitors for Type 2 Diabetes Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for DPP-4 Inhibitors for Type 2 Diabetes Treatment sales, projected growth trends, production technology, application and end-user industry.

DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Company

Novartis
Merck
Eli Lilly and Company
AstraZeneca
Takeda Pharmaceutical
Sanwa Kagaku Kenkyusho
Mitsubishi Tanabe Pharma
LG Life Sciences
Dong-A Pharmaceuticals
Bristol-Myers Squibb
Boehringer Ingelheim
DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Type

Alogliptin
Linagliptin
Saxagliptin
Vildagliptin
Sitagliptin
Others
DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Application

Hospitals and Clinics
Offline Retail Pharmacy
E-commerce and Internet Medical Care
DPP-4 Inhibitors for Type 2 Diabetes Treatment Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DPP-4 Inhibitors for Type 2 Diabetes Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of DPP-4 Inhibitors for Type 2 Diabetes Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DPP-4 Inhibitors for Type 2 Diabetes Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the DPP-4 Inhibitors for Type 2 Diabetes Treatment market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of DPP-4 Inhibitors for Type 2 Diabetes Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of DPP-4 Inhibitors for Type 2 Diabetes Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of DPP-4 Inhibitors for Type 2 Diabetes Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size, 2020 VS 2024 VS 2031
1.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Size Estimates and Forecasts (2020-2031)
1.4 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Estimates and Forecasts (2020-2031)
1.5 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market Dynamics
2.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Trends
2.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Drivers
2.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Opportunities and Challenges
2.4 DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Restraints
3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Manufacturers
3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Manufacturers (2020-2025)
3.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Manufacturers (2020-2025)
3.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Average Sales Price by Manufacturers (2020-2025)
3.4 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Manufacturers, Product Type & Application
3.7 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Market CR5 and HHI
3.8.2 Global Top 5 and 10 DPP-4 Inhibitors for Type 2 Diabetes Treatment Players Market Share by Revenue in 2024
3.8.3 2024 DPP-4 Inhibitors for Type 2 Diabetes Treatment Tier 1, Tier 2, and Tier 3
4 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Type
4.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Type Introduction
4.1.1 Alogliptin
4.1.2 Linagliptin
4.1.3 Saxagliptin
4.1.4 Vildagliptin
4.1.5 Sitagliptin
4.1.6 Others
4.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type
4.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Type (2020-2031)
4.2.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Type (2020-2031)
4.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Type
4.3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Type (2020-2031)
4.3.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Type (2020-2031)
5 DPP-4 Inhibitors for Type 2 Diabetes Treatment Market by Application
5.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Application Introduction
5.1.1 Hospitals and Clinics
5.1.2 Offline Retail Pharmacy
5.1.3 E-commerce and Internet Medical Care
5.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application
5.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Application (2020-2031)
5.2.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Market Share by Application (2020-2031)
5.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Application
5.3.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Application (2020-2031)
5.3.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Application (2020-2031)
6 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region
6.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region: 2020 VS 2024 VS 2031
6.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2020-2031)
6.2.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Region (2020-2025)
6.2.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region
7.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region
7.1.1 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2020-2025)
7.1.3 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue by Region (2026-2031)
7.1.4 Global DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (2020-2031)
7.2.2 North America DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (2020-2031)
7.3.2 Europe DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (2020-2031)
7.4.2 Asia-Pacific DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue (2020-2031)
7.5.2 South America, Middle East and Africa DPP-4 Inhibitors for Type 2 Diabetes Treatment Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Novartis
8.1.1 Novartis Comapny Information
8.1.2 Novartis Business Overview
8.1.3 Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Novartis DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
8.1.5 Novartis Recent Developments
8.2 Merck
8.2.1 Merck Comapny Information
8.2.2 Merck Business Overview
8.2.3 Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Merck DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
8.2.5 Merck Recent Developments
8.3 Eli Lilly and Company
8.3.1 Eli Lilly and Company Comapny Information
8.3.2 Eli Lilly and Company Business Overview
8.3.3 Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Eli Lilly and Company DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
8.3.5 Eli Lilly and Company Recent Developments
8.4 AstraZeneca
8.4.1 AstraZeneca Comapny Information
8.4.2 AstraZeneca Business Overview
8.4.3 AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 AstraZeneca DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
8.4.5 AstraZeneca Recent Developments
8.5 Takeda Pharmaceutical
8.5.1 Takeda Pharmaceutical Comapny Information
8.5.2 Takeda Pharmaceutical Business Overview
8.5.3 Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Takeda Pharmaceutical DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
8.5.5 Takeda Pharmaceutical Recent Developments
8.6 Sanwa Kagaku Kenkyusho
8.6.1 Sanwa Kagaku Kenkyusho Comapny Information
8.6.2 Sanwa Kagaku Kenkyusho Business Overview
8.6.3 Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Sanwa Kagaku Kenkyusho DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
8.6.5 Sanwa Kagaku Kenkyusho Recent Developments
8.7 Mitsubishi Tanabe Pharma
8.7.1 Mitsubishi Tanabe Pharma Comapny Information
8.7.2 Mitsubishi Tanabe Pharma Business Overview
8.7.3 Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Mitsubishi Tanabe Pharma DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
8.7.5 Mitsubishi Tanabe Pharma Recent Developments
8.8 LG Life Sciences
8.8.1 LG Life Sciences Comapny Information
8.8.2 LG Life Sciences Business Overview
8.8.3 LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 LG Life Sciences DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
8.8.5 LG Life Sciences Recent Developments
8.9 Dong-A Pharmaceuticals
8.9.1 Dong-A Pharmaceuticals Comapny Information
8.9.2 Dong-A Pharmaceuticals Business Overview
8.9.3 Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Dong-A Pharmaceuticals DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
8.9.5 Dong-A Pharmaceuticals Recent Developments
8.10 Bristol-Myers Squibb
8.10.1 Bristol-Myers Squibb Comapny Information
8.10.2 Bristol-Myers Squibb Business Overview
8.10.3 Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Bristol-Myers Squibb DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
8.10.5 Bristol-Myers Squibb Recent Developments
8.11 Boehringer Ingelheim
8.11.1 Boehringer Ingelheim Comapny Information
8.11.2 Boehringer Ingelheim Business Overview
8.11.3 Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Boehringer Ingelheim DPP-4 Inhibitors for Type 2 Diabetes Treatment Product Portfolio
8.11.5 Boehringer Ingelheim Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Value Chain Analysis
9.1.1 DPP-4 Inhibitors for Type 2 Diabetes Treatment Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 DPP-4 Inhibitors for Type 2 Diabetes Treatment Production Mode & Process
9.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 DPP-4 Inhibitors for Type 2 Diabetes Treatment Distributors
9.2.3 DPP-4 Inhibitors for Type 2 Diabetes Treatment Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.